We aim to gather integrated, comprehensive responses from clinicians in the future to allow them to discuss and define the optimal adjuvant therapy for premenopausal, HR-positive, HER2-negative, and early-staged patients with breast cancer. Here, ERBB2 is linked to breast carcinoma.